Molecular identification and antifungal susceptibility among clinical isolates of dermatophytes in Shiraz, Iran (2017‐2019)

Mycoses ◽  
2020 ◽  
Author(s):  
Zahra Zareshahrabadi ◽  
Alireza Totonchi ◽  
Ali Rezaei‐Matehkolaei ◽  
Macit Ilkit ◽  
Mehdi Ghahartars ◽  
...  
Keyword(s):  
Molecular Identification ◽  
Antifungal Susceptibility ◽  
Clinical Isolates

scholarly journals Molecular identification and antifungal susceptibility testing of Pucciniomycotina red yeast clinical isolates from Rio de Janeiro, Brazil

2019 ◽  
Vol 51 (1) ◽  
pp. 95-98
Author(s):  
Fabio Brito-Santos ◽  
Maria Helena Galdino Figueiredo-Carvalho ◽  
Rowena Alves Coelho ◽  
Jean Carlos Almeida de Oliveira ◽  
Raissa Vieira Monteiro ◽  
...  
Keyword(s):  
Molecular Identification ◽  
Rio De Janeiro ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Clinical Isolates ◽  
Red Yeast

scholarly journals Molecular Identification, Antifungal Susceptibility, and Geographic Origin of Clinical Strains of Sporothrix schenckii Complex in Mexico

2018 ◽  
Vol 4 (3) ◽  
pp. 86 ◽  
Author(s):  
Olga Rojas ◽  
Alexandro Bonifaz ◽  
Christian Campos ◽  
Rogelio Treviño-Rangel ◽  
Rafael González-Álvarez ◽  
...  
Keyword(s):  
Geographic Distribution ◽  
Molecular Identification ◽  
Antifungal Susceptibility ◽  
Geographic Origin ◽  
Sporothrix Schenckii ◽  
Etiological Agent ◽  
Clinical Isolates ◽  
The North ◽  
In Vitro Antifungal Susceptibility

Sporotrichosis is a subcutaneous mycosis caused by Sporothrix schenckii complex. The disease has been reported worldwide. However, the incidence of the etiological agent varies in its geographic distribution. We studied 39 clinical isolates of Sporothrix schenckii from diverse regions in Mexico, collected from 1998 to 2016. Molecular identification was performed by sequence analysis of the partial calmodulin gene. In vitro antifungal susceptibility to amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), posaconazole (PSC), fluconazole (FLC), terbinafine (TRB), caspofungin (CSF), anidulafungin (ANF), and micafungin (MCF) was evaluated. Thirty-eight isolates of S. schenckii complex were divided into five supported clades in a phylogenetic tree. The predominant clinical form was lymphocutaneous (92.3%), fixed cutaneous (5.1%), and disseminated (2.5%). Terbinafine exhibited the best in vitro antifungal activity, while fluconazole was ineffective against Sporothrix schenckii complex. Our results showed diverse geographic distribution of clinical isolates in eight states; definitive identification was done by CAL gen PCR-sequencing. In Mexico, S. schenckii is considered to be an etiological agent of human sporotrichosis cases, and lymphocutaneous is the most prevalent form of the disease. This study revealed four clades of S. schenckiisensu stricto by phylogenetic analysis. Furthermore, we report one case of S. globosa isolated from human origin from the North of Mexico.

Molecular identification and antifungal susceptibility of 75 clinical isolates of Trichophyton spp. from southern Brazil

2021 ◽  
pp. 101201
Author(s):  
Alessandra Koehler ◽  
Amanda Carvalho Ribeiro ◽  
Danielle Machado Pagani ◽  
Rodrigo Vettorato ◽  
Cibele Massotti Magagnin ◽  
...  
Keyword(s):  
Molecular Identification ◽  
Antifungal Susceptibility ◽  
Clinical Isolates ◽  
Southern Brazil

Comparison of the VITEK 2 antifungal susceptibility system with Etest using clinical isolates of Candida species

2017 ◽  
Vol 34 (3) ◽  
pp. 171-174 ◽  
Author(s):  
Wadha Alfouzan ◽  
Tahani Al-Enezi ◽  
Ebteehal AlRoomi ◽  
Vayalil Sandhya ◽  
Rachel Chandy ◽  
...  
Keyword(s):  
Candida Species ◽  
Antifungal Susceptibility ◽  
Clinical Isolates ◽  
Vitek 2

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies

2020 ◽  
Vol 75 (12) ◽  
pp. 3582-3585
Author(s):  
Olga Rivero-Menendez ◽  
Manuel Cuenca-Estrella ◽  
Ana Alastruey-Izquierdo
Keyword(s):  
Amphotericin B ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Scedosporium Apiospermum ◽  
In Vitro Activity ◽  
Scedosporium Dehoogii ◽  
Scedosporium Species

Abstract Objectives To evaluate the in vitro activity of olorofim, a new broad-spectrum antifungal with a novel mechanism of action, against a collection of 123 Spanish clinical isolates belonging to five Scedosporium species and Lomentospora prolificans. Methods The activity of olorofim against Scedosporium apiospermum (n = 30), Scedosporium boydii (n = 30), Scedosporium ellipsoideum (n = 10), Scedosporium aurantiacum (n = 20), Scedosporium dehoogii (n = 3) and Lomentospora prolificans (n = 30) was compared with that of amphotericin B, voriconazole, isavuconazole and micafungin by performing EUCAST and CLSI reference methods for antifungal susceptibility testing. Results Amphotericin B and isavuconazole showed MICs ≥2 mg/L for all the species evaluated and voriconazole was moderately active (GM, MIC50 and MIC90 values ≤2 mg/L) against all of them except L. prolificans. Micafungin was effective against S. apiospermum complex strains, but exhibited elevated MECs for S. dehoogii and S. aurantiacum. Olorofim showed low MICs for all the Scedosporium strains tested (GM values were lower than 0.130 and 0.339 by the EUCAST method and the CLSI method, respectively, for all of the species), including those belonging to the MDR species L. prolificans, for which GM values were 0.115 and 0.225 mg/L by the EUCAST method and the CLSI method, respectively, while the GMs for the rest of the antifungals evaluated were higher than 3.732 mg/L using both methodologies. Conclusions Olorofim displayed promising in vitro activity against the Scedosporium and L. prolificans strains tested, some of which have reduced susceptibility to the antifungals that are currently in use.

Sign in / Sign up

Export Citation Format

Share Document